INTRODUCTION
Malaria, a vector borne disease caused by parasites of the genus Plasmodium, remains a major global health problem (http://www.who.int/malaria/world_malaria_report_2011/en/). Despite important progress made by vector control initiatives and new artemisinin-based chemotherapy, the morbidity and mortality associated with this disease remain high, with an estimated 216-500 million episodes of malaria and 655,000 deaths each year. The need for a vaccine remains urgent, especially considering the recent reports of parasite artemisinin drug resistance and vector pyrethroid resistance.
The complex life cycle of Plasmodium will require a multifaceted approach to control/eradicate malaria. Optimism for development of vaccines as part of this multipronged approach has been raised by a recent phase III clinical trial of a vaccine based on a major sporozoite surface antigen, the circumsporozoite (CS) protein. 1, 2 This CS-based vaccine, termed RTS,S, targets the parasite at its pre-erythrocytic stages with the goal of preventing development of the erythrocytic stages responsible for clinical disease. The pre-erythrocytic stages are attractive immune targets as sporozoites inoculated by the mosquito vector and the exoerythrocytic forms that subsequently develop in the liver can be inhibited by antibody and by cellular immune responses, respectively. Successful prevention of the intra-erythrocytic cycle will also prevent development of parasite sexual stages responsible for transmission to the mosquito vector.
A key requirement for induction of potent humoral and cellular immunity is the dendritic cell (DC), which bridges the innate and adaptive immune response. Toll-like receptor (TLR) agonists that can be linked to antigens, such as the TLR5 agonist flagellin, function as strong adjuvants that induce maturation of DCs and upregulation of costimulatory molecules required for initiation of adaptive immunity. Viral and bacterial antigens linked to flagellin have shown promise as parenteral and mucosal vaccines in murine studies and clinical trials.
In a recent murine study, we demonstrated the immunogenicity, as well as the in vitro and in vivo protective efficacy, of antibodies elicited by a recombinant Plasmodium falciparum CS protein modified with the TLR5 ligand flagellin when delivered either subcutaneously (SC) or intranasally (IN) (Carapau, Mitchell, Nacer, Shaw, Othoro, Frevert et al., unpublished) . The vaccine was comprised of an Escherichia coli-expressed recombinant Salmonella enterica Typhimurium flagellin B protein, either full length (STF2) or truncated to remove the hinge region (STF2D), fused with T-and B-cell epitopes of P. falciparum CS protein or a nearly full-length CS protein ( Figure 1) . Sera of mice immunized IN or SC with the flagellin-modified CS constructs had similar levels of predominantly immunoglobulin G1 (IgG1) antibodies to CS or to flagellin. Antibody responses were dependent on flagellin as minimal or no antibodies to either CS or flagellin were obtained in tlr5 À / À mice. Immune sera from the IN immunized mice neutralized sporozoite infectivity in vitro when pre-incubated with viable transgenic PfPb sporozoites expressing P. falciparum CS repeats. 9 Consistent with the in vitro findings, IN immunized mice challenged by exposure to the bites of PfPb-infected mosquitoes had a 490% decrease in parasite 18S rRNA in liver extracts obtained 40 h post challenge. In contrast, mice immunized SC with flagellin-modified CS had lower levels of sporozoite-neutralizing antibodies detectable both in vitro and in vivo. These data provide the first demonstration of protective antibody-mediated immunity against sporozoites elicited by IN immunization with a flagellin-modified-P. falciparum CS and support the potential of developing a scalable, low-cost, needle-free malaria vaccine for the 40% of the world's population currently at risk of malaria.
In an effort to better understand the cellular environment in which protective immunity develops following IN immunization with flagellin-modified CS proteins, we analyzed the cell composition and structure of the nasopharynxassociated lymphoid tissue (NALT). Previous studies have demonstrated the immunogenicity of multiple malaria antigens when administered IN, [10] [11] [12] [13] but the interaction of malaria antigen with NALT has not been examined. The murine NALT resembles other non-encapsulated lymphoid organs, such as the Peyer's Patches (PP) of the gut-associated lymphoid tissue (GALT). However, murine NALT differs from GALT in terms of organogenesis as it begins to develop only after birth and does not require lymphotoxin-a or the retinoic acid receptor-related orphan receptor-g transcription factor as is required for GALT.
14 In contrast to lymph nodes (LNs), NALT and other mucosa-associated lymphatic tissues, such as GALT and the bronchus-associated lymphoid tissue, do not contain afferent lymphatics; instead, antigen transport into the lymphoid compartment requires specialized cells that transcytose or directly sample luminal antigen content.
In the current studies, we have used flow cytometry and confocal microscopy to examine NALT of mice immunized IN with flagellin-modified CS constructs. We demonstrate a cellular milieu characterized by expansion of B and T lymphocytes and influx of CD11 þ DCs into the NALT in vivo, and a pattern of CS antigen uptake into murine DCs in vitro, that potentially have key roles in vaccine-induced immune responses.
RESULTS

NALT structure and composition
Mice were immunized IN with flagellin-modified CS constructs previously shown to be immunogenic when delivered SC or IN to Balb/c or C57BL/6 mice (Carapau, Mitchell, Nacer, Shaw, Othoro, Frevert et al., unpublished) ( Figure 1 ). STF2D.CS was comprised of nearly full-length P. falciparum CS protein fused to a truncated flagellin, which lacks 300 aa of the hypervariable hinge region (STF2D), while STF2.(T1BT*) 4X contained four copies of immunodominant T-and B-cell epitopes from the P. falciparum CS protein, designated T1BT*, fused to fulllength flagellin (STF2). The murine NALT are a pair of lymphoid aggregates located on the soft palate on either side of the nasal passages, optimally sited to detect inhaled foreign material ( Figure 2) . The size of the NALT in mice immunized IN with either of the flagellin-modified CS constructs was increased when compared with naive mice when examined macroscopically ( Figure 3) . Measurements of the NALT area from trichrome-stained sections showed an approximately twofold increase in the NALT of immunized as compared with that of naive mice. Enlargement of the NALT was due to the presence of the flagellin TLR5 agonist, as IN immunization with flagellin alone elicited a similar increase in size of the NALT (data not shown).
NALT-associated lymphoid cell populations
Flow cytometric analysis of the NALT cell populations in naive C57BL/6 mice revealed that the predominant NALT cells were B cells, while CD3 þ T cells and CD11c þ DCs accounted for In contrast, while the ratio of T and B cells remained similar in naive and immunized mice, there was a dose-dependent increase in the percentage of CD11c þ DCs in the NALT of the immunized C57BL/6 mice ( Figure 4c) . A modest increase (B50%) in CD11 þ DCs was observed following the first immunization with STF2D.CS (3.1%) or STF2D (2.8%) as compared with naive (2.0%). Following the fourth immunization, there was a 2-3-fold increase in the percentage of CD11 þ DCs observed in STF2D.CS (7.1%) or STF2D (6.0%) immunized mice as compared with naive mice (2.2%) (Po0.05). The 4twofold increase in CD11c þ DCs in the mice immunized with flagellin (STF2D) only indicated that the increase in DCs was due to flagellin stimulation of NALT.
Consistent with the flow cytometric analysis of NALT cell populations, immunolabeling of freshly excised snap-frozen and fixed NALT cryosections confirmed that the majority of lymphocytes in the naive NALT were B220 þ B cells ( Figure 5 ). Because the position of B-and T-cell regions within the NALT parenchyma is variable, 15 NALTs were analyzed longitudinally. 
NALT microvasculature
To visualize routes by which DCs would migrate to and enter the NALT, sections were labeled with anti-PECAM-1 (anti-platelet endothelial cell adhesion molecule 1) to detect endothelia of blood vessels and with anti-LYVE-1, a marker for lymphatic endothelia. 16 Although blood microvessels were distributed throughout the lymphatic tissue of the NALT, lymphatic vessels were primarily located in the posterior portion of the NALT and oriented longitudinally along the connective tissue of the soft palate underlying the NALT ( Figure 7) . Consistent with the lack of afferent lymphatics in NALT, this vascular distribution suggests hematogenous influx of DCs via high endothelial venules. Following antigen uptake, DCs could directly interact with T cells within the NALT or exit via efferent lymphatics towards the draining cervical LN, to induce adaptive immune responses. Consistent with a role of the draining LN (dLN) in the immune responses, we found the cervical, superficial parotid, and mandibular LN were increased in size following immunization with flagellin or flagellinmodified CS (data not shown). Of interest, cells of a dendritic morphology were found that appeared to extend dendrites across the epithelium into the nasal cavity (Figure 8c, d , and f). These cells are considered DCs based on their shape, location in close proximity to the epithelium and staining with anti-CD11c antibody (Figure 8h) . DCs within the gut are known to extend dendrites across the intact epithelium to sample luminal antigens. 18, 19 However, CS antigen could not be detected within DCs in freshly excised snap-frozen and fixed NALTs immunolabeled with MAB 2A10, specific for P. falciparum CS repeats, at 10 min, 30 min, 1 h, or 3 h post IN immunization. Most likely, our staining methods were not sensitive enough to detect the limited amount of antigen these cells internalize in vivo.
DC uptake of flagellin-modified CS in vitro
As we were unable to detect intracellular CS protein in tissue sections, we examined the uptake of flagellin-modified CS by DCs in vitro using murine bone marrow-derived DCs (BMDCs). To synchronize antigen uptake, BMDCs were incubated with or without 100 mg ml À 1 of flagellin-modified CS for 30 min on ice followed by 30 min incubation at 37 1C. Both STF2.(T1BT*) 4X and STFD.CS were taken up by DCs within 30 min, as measured by labeling with MAB 2A10 specific for P. falciparum CS (Figure 9a) . A stronger intracellular signal was observed in BMDCs incubated with STFD.CS compared with STF2.(T1BT*) 4X . However, these higher levels may reflect increased binding of MAB 2A10 due to the more numerous repeats present the in full-length CS protein, which contains 44 tetramer repeats, as compared with 24 tetramer repeats present in the STF2.(T1BT*) 4X construct ( Figure 1) .
The intracellular distribution of malaria antigen within the DCs ranged from small vesicles, presumably early endosomes, to larger vesicles (possibly late endosomes), as well as distribution throughout the cytosol (Figure 9b ). After 30 min of incubation with STFD.CS, the majority (55%) of the CS þ DCs had a cytosolic labeling pattern, suggesting that flagellin-modified CS readily translocated from the endocytic compartment into the cytosol of DCs.
Quantification of the BMDC staining profiles indicated that intracellular distribution of flagellin-modified CS was dose dependent (Figure 9c ). When labeled with MAB 2A10, BMDCs incubated with 10 mg of STF (T1BT*) 4X had 60% CS þ positive cells while cells incubated with 100 mg ml À 1 were 75% antigen positive. Cytosolic CS was detected in 5.13% of BMDCs incubated with the high dose of antigen (100 mg ml
), while none of the cells at the lower concentration had detectable CS in the cytosol. The proportion of vesicular and/or cytosolic intracellular staining patterns differed for the two flagellin-CS constructs. BMDCs incubated with 100 mg ml À 1 STFD.CS had higher levels of positive cells (88%) with higher levels of cytosolic distribution (13%), when compared with DC cultures incubated with STF2.(T1BT*) 4X . Although these differences may reflect heterogeneity in activation states or DC subsets within the BMDC cultures, increased detection of STFD.CS by MAB 2A10, as noted above, is also a possible explanation for these differences.
The presence of cytosolic flagellin-modified CS led to alterations in BMDC morphology. The cells exhibiting vesicular antigen remained well spread, with a morphology similar to cells that did not take up flagellin-modified CS (Supplementary Figure S2b,c online) . In contrast, cells with a cytosolic antigen appeared rounded. In confocal 3D data isosurfaces representing the intracellular distribution of CS protein, cells with vesicular CS protein are well spread (Supplementary Figure S2e online To better understand the immune mechanisms functioning in IN immunization, we examined the NALT structure and cell populations of mice immunized with flagellin-modified CS constructs. When examined at various time points post immunization, using flow cytometry and confocal microscopy, the cellular composition in the NALT was found to differ from LNs. A predominance of B cells was observed for NALT of mice immunized with flagellin-modified CS (Figures 4 and 5) , similar to the predominance of B cells in PP, potentially making NALT a privileged site for antibody production. Although the NALT doubled in size following immunization with flagellinmodified CS constructs, a low T:B cell ratio persisted with a predominant population of B cells. Previous reports showed that clonal expansion of B and T cells in the NALT could occur in a manner that maintains this low T:B cell ratio. 15 Immunization with flagellin-modified CS led to an increase in numbers of CD11c þ DCs located under the single-layer epithelium of the NALT (Figures 4, 6 and 8 and Supplementary  Figure S1 online). The interaction of antigen with TLR5 expressed on NALT FAE 22 may stimulate chemokine secretion to increase influx of DCs. Expression of occludin and certain claudins has been implicated in DC entry into the epithelium, while ZO-1 (zonula occludens protein 1) upregulation was proposed to allow DC detachment for migration to the dLN. 18 DCs, in addition to functioning as antigen-presenting cells for T and B cells within the NALT, could therefore also transport malaria antigen via efferent lymphatics (Figure 7) to the dLN. In addition to the increase in size of the NALT, we found the cervical, superficial parotid, and mandibular LN increased in size following immunization with flagellin or flagellin-modified CS. Figure 8 Composition of the epithelium covering the nasopharynxassociated lymphoid tissue (NALT). Hematoxylin and eosin-stained paraffin sections demonstrate that while the epithelium that lines the majority of the nasal cavity contains (a) a large number of goblet cells (black arrow), these mucus-secreting cells are rare (b) in the epithelium covering the NALT (black arrow). M cells, which are typically located in the apical portion of the NALT epithelium, can be identified by (c) the lack of cilia (black arrow). In (c, d) trichrome-stained paraffin sections and (e, f) toluidine blue-stained Epon sections, occasionally, cells of a dendritic shape can be found, whose dendrites extend across the epithelium into the nasal cavity (c and d, white arrows; f, black arrows), in addition to M cells (e, black arrow). (g) By confocal microscopy, M cells (green) were located apical from the epithelial nuclei (blue). M cells were labeled with GS-IB 4 lectin conjugated to Alexa Fluor 568, nuclei were stained with Hoechst. (h) The majority of the CD11c þ dendritic cells (DCs; red) were located in the sub-epithelial portion of the lymphoid tissue, while some DCs have infiltrated the epithelium (white arrows). DCs were detected by confocal microscopy using biotinylated anti-mouse CD11c followed by streptavidin Alexa Fluor 633. Bars ¼ 10 mm.
Previous studies using ovalbumin-tagged Streptococcus pyogenes and Lactobacillus murinus and ovalbumin (OVA)-specific, MHC class II-restricted T cell receptor transgenic mice cells show a higher frequency of T-cell division in NALT than in cervical LN in early responses, followed by the later expansion in the cervical dLN, suggesting that NALT can serve as the inductive site for CD4 þ T cells, as well as B cells. 23, 24 Antigen uptake into the NALT is thought to occur via several routes: (1) transcytosis through M cells, (2) transport across the columnar epithelia, and (3) direct luminal sampling via DC dendrites. Our staining of NALT sections detected GS-IB 4 lectin-positive M cells in the epithelial layer that may function in the uptake of flagellin-modified CS (Figure 8 ), similar to their role in antigen transport and the development of mucosal immune responses in intestinal PP. 25 The unique M-cell pocket, formed by invagination of the epithelial basal membrane, is thought to function as an intraepithelial docking site for lymphocytes, macrophages, and DCs. In addition to antigen uptake, transcriptional analysis has detected TLR5 expression in M cells, as well as FAE cells of PP. 22 GALT M cells and FAE have been shown to secret C-C ligand chemokines (CCL9, CCL25, and CCL20) that attract DCs. CCL20 in GALT is upregulated in response to danger signals, such as flagellin on S. enterica Typhimurium. 26 Interaction of flagellin-modified CS with TLR5 on NALT M cells or FAE may induce chemokines that attract DCs to the NALT epithelium.
In the current studies, in addition to the increased numbers of DCs, intercellular dendrites of DCs extending beyond the ciliated epithelial cell layer were noted in NALT from mice immunized with flagellin-modified CS (Figure 8c, d, and f) . These structures were consistent with previously reported trans-epithelial ''balloon'' shaped dendrites extended by CD11c þ DCs into the gut lumen in C57BL/6 mice. 19, 27 Direct luminal sampling of nasal cavity via DC dendrites is consistent with current models for sampling of bacteria in gut or airways. 28, 29 Dendrite extensions of DCs within nasal tissue of patients suffering allergic rhinitis have also been reported. 30 The number of DC dendrites has been shown to increase in response to the presence of Salmonella in the gut that was mediated via fractalkine receptor (CX3CR1) ligand CX3CL1 interaction. 19, 27 TLR5 signaling on epithelial cells, as well as the direct signaling through TLR5 on DCs, could have a role in dendrite formation. 31 The adjuvant activity of flagellin has been shown to be mediated by activation of CD11c þ DCs via TLR5 signaling that also leads to enhanced antigen uptake. 32 In the current studies, flagellin-modified CS constructs were readily taken up by murine DCs in vitro, with the internalized CS antigen distributed either in small and large vesicles, presumably early/late endosomes, or throughout the cytosol ( Figure 9 and Supplementary Figure S2 online). Cytosolic distribution has been observed with other flagellin-modified antigens. 4, 33 The adjuvant activity of alum is dependent on destabilization of lysosome membranes and leakage into the cytosol with subsequent activation of the NRLP3 inflammasome. 34 Cytosolic flagellin injected by TIII secretion system of intracellular Salmonella is known to activate the nucleotide-binding oligomerization domain-like receptor family caspase activation and recruitment domain-containing protein 4 (IPAF) inflammasome leading to host cell death by pyroptosis. 35, 36 The pycnotic nuclei noted in cells with large amounts of cytosolic CS antigen (Supplementary Figure S2 online) is consistent with inflammasome-induced pyroptosis, and the role of the inflammasome in the adjuvant activity of flagellin remains to be explored.
Presence of the flagellin-modified CS in the cytosol may mimic the cytosolic localization of native CS protein, which is shed by the sporozoite into the cytoplasm during traversal of Kupffer cells and invasion of liver hepatocytes. 37, 38 Murine CS-specific CD8 þ cells elicited by immunization with irradiated sporozoites, as well as a Salmonella-vectored CS protein vaccine, were protective in murine malaria models. 39, 40 However, CS-specific CD8 þ T cells were not detected in flagellin-modified CS-immunized mice (Carapau, Mitchell, Nacer, Shaw, Othoro, Frevert et al., unpublished), consistent with the inability of C57BL/6 (H-2 b ) mice to mount class I restricted responses to CS proteins. 41, 42 Nevertheless, the cytosolic distribution of antigen detected in these studies is consistent with the ability of flagellin-modified bacterial and viral antigens to elicit protective CD8 þ T-cell-mediated immunity. 4, 33 Protection in the flagellin-modified CS-immunized mice was found to correlate with sporozoite-neutralizing antibodies that reduced parasite burden in vitro and in vivo following challenge with rodent parasites expressing P. falciparum CS repeats (Carapau, Mitchell, Nacer, Shaw, Othoro, Frevert et al., unpublished). The imaging of the NALT in the flagellinmodified CS-immunized mice emphasizes the challenges of IN vaccination and suggest several strategies to enhance IN-induced malaria-specific humoral immunity. The mucociliary environment within the NALT, provided by the ciliated epithelial cells and mucous-producing goblet cells (Figure 8) , functions in rapid clearance of inhaled material, which, unfortunately, includes IN delivered vaccines. That limited antigen uptake was a factor in immunogenicity of the flagellinmodified CS is suggested by the need for 4-5 IN doses to elicit peak antibody responses (Carapau, Mitchell, Nacer, Shaw, Othoro, Frevert et al., unpublished). The use of mucoadhesive adjuvants such as chitosan, a cationic copolymer of N-acetylglucosamine and glucosamine derived from crustacean shells that readily binds to the negatively charged nasal mucin, has been successfully used to enhance immunogenicity of IN vaccines. [43] [44] [45] The chitosan particulate formulations served both to prolong antigen residence time within the nasal cavity and to enhance uptake by antigen-presenting cells. Our recent studies have shown that SC or intramuscular immunization with P. falciparum CS microparticles can elicit enhanced antirepeat antibody and T-cell responses in mice and non-human primates. 46, 47 These recent findings suggest that particulate formulations of flagellin-CS combined with a mucoadhesive adjuvant such as chitosan would improve delivery and uptake of CS vaccines in the NALT. In addition, although the specific roles of M cells and CD11c þ DCs, as well as DC sampling of luminal antigen, in immunogenicity of IN delivered flagellin-CS proteins remain to be defined, targeting of NALT antigen-presenting cells may further enhance immunogenicity. NALT M cells were specifically labeled with the GS-IB4 lectin ( Figure 8 ) and the addition of lectin tags to target antigens to M cells has been shown to enhance immunogenicity of IN viral vaccines. 48 In addition, the inclusion of a DC-specific nasal adjuvant, such as the fms-like tyrosine kinase 3 ligand, has been shown to increase NALT DC numbers and expression of co-stimulatory molecules and systemic antibody responses to IN recombinant protein vaccines 49 and may further enhance immunogenicity of IN flagellin-modified CS vaccines.
An optimized IN needle-free malaria vaccine would enable mass immunization campaigns for control of epidemic and endemic malaria and facilitate malaria eradication efforts by reducing costs and eliminating the need for medical personnel to administer the vaccine. In humans, the functional correlate of the rodent NALT is the Waldeyer's ring, a morphologically distinct lymphoid structure composed of the nasopharyngeal adenoid and pairs of palatine, tubal, and lingual tonsils. 29 The Waldeyer's ring is well developed during childhood, and thus nasal vaccines may be particularly promising for infants and young children who are at highest risk of severe P. falciparum malaria and death. Recent Phase III trial clinical trials of RTS,S, which is administered intramuscularly in a potent liposome adjuvant formulation, have shown protection against clinical disease in 30-55% of immunized infants, Flagellin-modified P. falciparum CS proteins. Design, production, and purification of flagellin-modified P. falciparum constructs were performed as described for flagellin-modified bacterial and viral vaccines. [3] [4] [5] Two E. coli-expressed fusion proteins were constructed, STF2D.CS and STF2.(T1BT*) 4x , based on the P. falciparum CS protein (Figure 1 ). STF2D.CS was comprised of nearly full-length P. falciparum CS fused to the C-terminus of a truncated S. enterica serovar Typhimurium type B flagellin (Flij) that lacks 300 aa of the hypervariable hinge region (STF2D). The second construct, STF2.(T1BT*) 4x , contained full-length S. enterica Typhimurium flagellin (STF2) fused to 4 copies of the tri-epitope T1BT* sequence representing immunodominant T-and B-cell epitopes of P. falciparum CS protein recognized by sera and cells of immunized individuals. The purified flagellin-modified CS constructs contained o0.01 EU mg À 1 endotoxin levels, based on a Limulus Amoebocyte Lysate kit QCL 1000 (Cambrex, Walkersville, MD), and stimulated cytokine production by cells transfected with a human TLR5 gene.
Immunization. C57BL/6 and BALB/c mice (Jackson Laboratories, Bar Harbor, ME) were housed in AAALAC approved Animal Facilities according to NYU School of Medicine IACUC approved protocols. Mice Z8 weeks were used as NALT organogenesis does not begin until after birth and reaches maturation at B8 weeks of age.
14 Mice were immunized at 2-week intervals with 10-50 mg of flagellin-modified CS by placing10 ml in each nare of anesthetized mice. Controls included mice immunized IN with full-length or truncated flagellin without CS (STF2, STF2D) or with phosphate-buffered saline (PBS).
DC cultivation. Murine BMDC, obtained from the tibias and femurs of naive mice, were filtered through a 100-mm mesh (Corning Life Sciences, Oneonta, NY), and the red cells were lysed. The washed cell pellet was resuspended in complete Dulbecco's modified Eagle's medium supplemented with 30% conditioned medium obtained from cultures of Ag8653 cells transfected with recombinant granulocyte-macrophages colony-stimulating factor (provided by Dr Ana Rodriguez, New York University, NY). Cells were cultured at 37 1C, 5% CO 2 , and humid atmosphere, and medium was changed every other day.
To assess antigen uptake, murine BMDCs were plated into eightwell Permanox Lab-Tek chamber slides plates at 2 Â 10 5 per well and incubated with 10 or 100 mg ml À 1 STF2D.CS or STF2.(T1BT*) 4X at 4 1C for 30 min to allow synchronized binding, followed by incubation at 37 1C to allow antigen uptake. Cells were fixed in situ with 4% paraformaldehyde in PBS and permeabilized with 0.25% Triton X-100 in PBS. Intracellular antigen was detected by labeling with 10 mg ml À 1 MAB 2A10, specific for P. falciparum CS protein, followed by biotinylated goat anti-mouse IgG (Invitrogen, Eugene, OR) and streptavidin-Qdots 655 (Invitrogen). Nuclei were stained with Hoechst 33342 (Invitrogen).
NALT preparation. NALTs were removed from immunized or naive mice using a standard protocol. 50 To visualize the position of the 51 Mice were intravenously injected with 100 ml of a 1% Evans blue solution in PBS and killed 3 h later. NALTs were either dissected from the palate or analyzed in situ. Specimens were photographed with a Leica MZ16 FA stereomicroscope (Leica Microsystems, Buffalo Grove, IL) equipped with a Leica DFC 300 FX camera (Leica Microsystems). Data were imported into Adobe Photoshop Elements (San Jose, CA) for further processing.
NALT histology. NALTs from naive mice were fixed with 1% glutaraldehyde in PBS, postfixed with 1% OsO 4 and 1.5% K 3 Fe(CN) 6 , stained en bloc with 0.5% uranyl acetate, dehydrated in ethanol, and embedded in Epon. Semithin sections were stained with toluidine blue. For morphological comparison of NALTs from immunized and naive mice, noses were separated from the head, cleaned from connective tissue, fixed for 24 h in 4% paraformaldehyde in PBS. The snouts were decalcified for 5-6 days in 0.42 M EDTA, pH 7.1 52 and embedded in paraffin. Sections were stained with trichrome or hematoxylin and eosin. Cryosections were prepared from the same specimens and stained with Giemsa.
NALT dLN. To identify changes in the dLN associated with IN immunization, mice were administered Higgins Waterproof India Ink (Staples, New York, NY; No. 4425), 53 either in combination with Sigma Ribi Adjuvant System (Sigma, St Louis, MO; S6322) or flagellin (STF2). Briefly, the adjuvants were reconstituted/diluted with sterile PBS and mixed 1:1 with India ink. Mice were administered 30 ml (15 ml per nare) of these mixtures, either IN or SC, and killed 14 post first dose or 7 days post second dose. The LN were excised and examined for the presence of ink and changes in size in comparison to control mice.
Immunolabeling and confocal microscopy. For confocal microscopy, the palate was removed, immediately placed NALT-side down into OCT (optimal cutting temperature), frozen in liquid nitrogen, and stored at À 801C until further use. Frozen sections cut with a Leica CM 3050S cryostat (Leica Microsystems) were briefly immersed in ice-cold acetone, air dried overnight, and stored at À 201C. Slides were fixed with ice-cold acetone and labeled with rat anti-mouse CD45R B220 (clone RA3-6B2; eBioscience, San Diego, CA) to detect B cells, Armenian hamster anti-CD3 (clone 145-2C11; BD Biosciences, San Jose, CA) to detect T cells and biotinylated anti-CD11c (clone N418; eBioscience) to detect DCs. Secondary antibodies were donkey anti-rat Alex Fluor 488 or 546 (Invitrogen) or anti-Armenian hamster DyLight 488 or 594 (BioLegend, San Diego, CA). Streptavidin Alexa Fluor 633 (Invitrogen) was used to detect biotinylated primary antibodies. M cells were detected by labeling frozen sections or whole-fixed NALTs with the M-cell-specific Griffonia simplicifolia lectin GS-IB 4 conjugated to Alexa Fluor 568 (Invitrogen). For whole NALT preparations, mice were perfused with heparinized PBS followed by 4% paraformaldehyde in PBS. The palate containing the NALT was removed and fixation continued for 1 h at room temperature. 17 After washing with PBS, palates were incubated for 1 h with 20 mg ml À 1 GS-IB 4 conjugated to Alexa Fluor 568. NALTs were washed with PBS and imaged immediately by confocal microscopy. Sections were labeled accordingly for 1 h at room temperature following the manufacturer's instructions. Blood vessels were labeled with 5 mg ml À 1 mouse anti-CD31 conjugated to Alexa Fluor 647 (BioLegend). Lymph vessels were detected with 5 mg ml À 1 rat anti-mouse LYVE-1 followed by donkey anti-rat IgG conjugated to Alexa Fluor 488 (Invitrogen).
Specimens were analyzed with an inverted Leica TCS SP2 AOBS confocal system (Leica Microsystems) and 2D and 3D data acquired with Leica Confocal Software (Leica Microsystems). Imaris 7.4 (Bitplane, Saint Paul, MN), Image-Pro Plus (Media Cybernetics, Bethesda, MD), AutoDeBlur (Media Cybernetics), and NIH ImageJ (NIH, Bethesda, MD) were used for further image processing and deconvolution.
Flow cytometry. After removal from the palate, NALTs from three mice within each group were pooled and transferred into RPMI supplemented with 15% fetal bovine serum (HyClone, Logan, UT). Individual cells were obtained by filtering NALTs through a 100-mm sieve (Corning, Corning, NY). Cells were incubated 30 min on ice with a 1:200 dilution of Fc block (CD16/32, BD Biosciences) in FACS (fluorescence-activated cell sorter) buffer (3% fetal bovine serum in PBS). Lymphocyte populations were detected for 30 min on ice with allophycocyanin-conjugated anti-mouse CD3e antibody (clone 145-2C11, BioLegend), allophycocyanin-conjugated anti-mouse CD11c (clone N418, BioLegend), and PerCP/Cy5.5-conjugated rat antimouse B220 (clone RA3-6B2, BioLegend), diluted 1:100 in FACS buffer followed by fixation with 4% paraformaldehyde in PBS. Data were acquired with a FACSCaliber cytometer (Becton Dickinson, Franklin Lakes, NJ) and analyzed with FlowJo software (Tree Star, Ashland, OR).
Statistics. One-way analysis of variance and one-tailed t-test analyses were performed with GraphPad Software Prism 5.04 (La Jolla, CA).
